Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 6/20 | 0.64 |
| ▸ | REN | P00797 | 5/20 | 0.64 |
| ▸ | NPY2R | P49146 | 7/20 | 0.61 |
| ▸ | NPY4R | P50391 | 7/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.61 |
| ▸ | NPY1R | P25929 | 5/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30364495 | 0.87 | TFPI (0.68) | TFPIRENNPY2RNPY4RNPY5R | |
| Melectin SCHEMBL30448502 | 0.87 | REN (0.62) | TFPIREN | |
| SCHEMBL29542556 | 0.86 | TFPI (0.70) | TFPINPY2RNPY4RNPY5RNPY1R | |
| Drosocin SCHEMBL29539177 | 0.86 | NPY2R (0.66) | TFPIRENNPY2RNPY4RNPY5R | |
| SCHEMBL29776068 | 0.86 | TFPI (0.65) | TFPIRENNPY2RNPY4RNPY5R | |
| SCHEMBL29525763 | 0.84 | KDM1A (0.63) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29614957 | 0.84 | TFPI (0.63) | TFPINPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29778186 | 0.84 | AGTR2 (0.77) | TFPIRENNPY2RNPY4RNPY5R | |
| SCHEMBL31418387 | 0.84 | TFPI (0.63) | TFPIRENNPY2RNPY4RNPY5R | |
| SCHEMBL32930844 | 0.83 | AGTR1 (0.70) | TFPIRENNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026042043-A1 | ANTIMICROBIAL COMPOSITIONS FOR HYGIENE APPLICATIONS | ITC LIMITED (IN) | 2026-02-26 | — | — | WO | claimed |
| EP-4681776-A2 | ANTIMICROBIAL THERAPY | The Regents of the University of California (US) | 2026-01-21 | — | — | EP | claimed |
| EP-4677075-A2 | TARGETING CELLS IN STRESSED GROWING CONDITIONS | SNIPR Biome ApS (DK) | 2026-01-14 | — | — | EP | claimed |
| US-20250339474-A1 | ANTIMICROBIAL THERAPY | UNIV CALIFORNIA (US) | 2025-11-06 | — | — | US | claimed |
| EP-3291824-B1 | ANTIMICROBIAL THERAPY | UNIV CALIFORNIA (US) | 2025-11-05 | — | — | EP | claimed |
| US-20250243208-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-07-31 | — | — | US | claimed |
| US-20250206734-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-06-26 | — | — | US | claimed |
| US-20250154174-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-05-15 | — | — | US | claimed |
| WO-2025042736-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025042730-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | claimed |
| EP-4387638-A1 | GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN AND USE AS A LIVE DELIVERY AND PRODUCTION SYSTEM | BiomEdit, LLC (US) | 2024-06-26 | — | — | EP | claimed |
| EP-4329834-A1 | REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES | Avita Medical, Inc. (US) | 2024-03-06 | — | — | EP | claimed |
| US-20230355671-A1 | Upregulation of Cathelicidin Gene Expression as an Adjuvant to Other Treatments for Diseases | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-11-09 | — | — | US | claimed |
| US-20230134704-A1 | A METHOD OF TREATING CANCER BY UPREGULATING CATHELICIDIN GENE EXPRESSION AND INFUSING NATURAL KILLER CELLS | BARRON ANNELISE E (US) | 2023-05-04 | — | — | US | claimed |
| WO-2023049155-A1 | GENETICALLY MODIFIED BACILLUS SUBTILIS STRAIN AND USE AS A LIVE DELIVERY AND PRODUCTION SYSTEM | BIOMEDIT, LLC (US) | 2023-03-30 | — | — | WO | claimed |
| EP-4133115-A1 | GENETICALLY REPROGRAMMED MYCOPLASMA BACTERIA AND USES THEREOF | Fundació Centre de Regulació Genòmica (ES) | 2023-02-15 | — | — | EP | claimed |
| WO-2022231904-A1 | REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES | AVITA MEDICAL, INC. (US) | 2022-11-03 | — | — | WO | claimed |
| US-20220339202-A1 | REGENERATIVE BIOACTIVE SUSPENSION DERIVED FROM FRESHLY DISAGGREGATED TISSUE AND METHODS OF USE IN CLINICAL THERAPIES | AVITA MEDICAL, INC. | 2022-10-27 | — | — | US | claimed |
| CN-107735098-B | Antimicrobial therapy | 加利福尼亚大学董事会 | 2022-07-29 | — | — | CN | claimed |
| EP-3943160-A1 | AMMONIA OXIDIZING BACTERIA FOR TREATMENT OF ACNE | Aobiome LLC (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154174-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | TFPI 701/4885REN 1003/4885NPY2R 152/4885 |
| US-20250243208-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | TFPI 701/4885REN 1003/4885NPY2R 152/4885 |
| US-20250206734-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | TFPI 701/4885REN 1003/4885NPY2R 152/4885 |
| US-20250339474-A1 | ANTIMICROBIAL THERAPY | LCT, HM13, ITCH | TFPI 710/4885REN 955/4885NPY2R 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.